Azenta, Inc. (AZTA) company profile
Close on Nov 17, 2026Market cap $2.01BP/E –Yield –
About Azenta
Special Industry Machinery, NEC, SIC 3559
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences sector. The company operates through two primary segments: Sample Management Solutions and Multiomics. Its Sample Management Solutions business offers automated storage systems, cryogenic devices, sample repository services, automated tubes, controlled-rate thawing devices, and laboratory consumables. Through its Multiomics segment, the company delivers genomic services such as gene sequencing, gene synthesis, and bioinformatics analysis. Azenta serves approximately 14,000 clients globally, including pharmaceutical and biotechnology enterprises, research hospitals, academic organizations, and government institutions.
The company is headquartered in Burlington, Massachusetts, and conducts operations across North America, Europe, and Asia. It generates sales in approximately 95 countries and employs around 3,000 individuals worldwide. Azenta maintains principal manufacturing facilities in the United States and the United Kingdom, alongside a network of 14 genomic services laboratories located across the United States, China, the United Kingdom, Germany, and Japan.
Summary of the business section of Azenta's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Azenta, Inc.
- Founded
- 1978
- Headquarters
- Burlington, MA
- Address
- 200 Summit Drive, 6th Floor 01803
- Phone
- (978) 262-2400
- Website
- azenta.com
- Employees
- 3,000, Sep 30, 2025
- Industry
- Special Industry Machinery, NEC
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- AZTA
- Former tickers
- BRKS until Dec 1, 2021
- Exchange
- Nasdaq
- IPO date
- Feb 2, 1995
- Shares outstanding
- 44M, Aug 3, 2026
- Public float
- $1.00B, Mar 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 933974
- CUSIP
- 114340102
- ISIN
- US1143401024
- FIGI
- BBG000DX9JV7
- Share class FIGI
- BBG001S8F1B8
- LEI
- 35ZN6X1ANPH25YN32Y17
- EIN
- 04-3040660
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Marotta | President and CEO, Director | 213,194 |
| Erik J. Bello | VP Chief Accounting Officer | 10,401 |
| Lawrence Y. Lin | EVP, CFO and Treasurer | 129,048 |
| Ephraim Starr | SVP, Gen Counsel & Secretary | 105,711 |
| Olga Pirogova | SVP and CHRO | 63,895 |
| William E. Martin Iii | President Multiomics | 50,638 |
| Martin D. Madaus | Interim CEO | 41,308 |
| Ginger Zhou | SVP and GM, Multiomics | 38,755 |
| Violetta Hughes | VP, Chief Accounting Officer | 9,603 |
| David Dong Wang | SVP & GM, SMS | 23,974 |
| Herman Cueto | EVP, Chief Financial Officer | 23,892 |
| Jason Joseph | SVP, General Counsel, Secy. | 112,564 |
| William L. Cornog | Director | 45,498 |
| Quentin Koffey | Director | 4,622,450 |
| Erica McLaughlin | Director | 22,521 |
| Frank Casal | Director | 21,803 |
| Robyn C. Davis | Director | 33,627 |
| Tina Susan Nova | Director | 15,772 |
| Dipal Doshi | Director | 9,703 |
| Alan J. Malus | Director | 17,035 |
| Didier Hirsch | Director | 3,465 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr John Marotta | $10.37M | $6.82M | $2.06M | $62 | $102 |
| FY2025 Stephen Schwartz | $0 | $0 | $2.06M | $62 | $102 |
| FY2024 Mr John Marotta | $638.81K | $668.79K | $1.91M | $105 | $132 |
| FY2024 Stephen Schwartz | $6.12M | $1.73M | $1.91M | $105 | $132 |
| FY2023 | $5.55M | $5.75M | $1.59M | $109 | $109 |
| FY2022 | $4.67M | -$8.29M | $2.36M | $93 | $110 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| John Marotta President and Chief Executive Officer | $900.00K | – | $8.39M | $1.06M | $21.46K | $10.37M | +1524% |
| Lawrence Lin Executive Vice President and and Chief Executive Officer | $463.15K | $250.00K | $2.78M | $398.09K | $13.79K | $3.91M | – |
| Herman Cueto Former Executive Vice President and Chief Financial Officer (5) | $100.00K | $240.00K | – | – | $430.00K | $770.00K | -78% |
| Ephraim Starr Senior Vice President, General Counsel/Corporate Secretary | $191.08K | – | $2.14M | $143.71K | $5.19K | $2.48M | – |
| Jason W. Joseph Former Senior Vice President, General Counsel/Corporate Secretary | $355.62K | – | $1.39M | $321.25K | $205.75K | $2.27M | -6% |
| Olga Pirogova Senior Vice President and Chief Human Resources Officer | $391.69K | – | $1.04M | $252.50K | $16.50K | $1.70M | +10% |
| Ginger Zhou Senior Vice President, President GENEWIZ | $410.12K | – | $867.59K | $261.43K | $9.23K | $1.55M | -2% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“In total, we employ approximately 3,000 full-time employees, part-time employees and contingent workers worldwide as of September 30, 2025, primarily in the United States.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?